402 related articles for article (PubMed ID: 33431788)
41. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
[TBL] [Abstract][Full Text] [Related]
42. Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome.
Zimmermann N; Acosta AM; Kohlhase J; Bartsch O
Eur J Hum Genet; 2007 Aug; 15(8):837-42. PubMed ID: 17299436
[TBL] [Abstract][Full Text] [Related]
43. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
44. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas P; Mortazavi A; Picus J; Hahn NM; Milowsky MI; Hart LL; Alva A; Bellmunt J; Pal SK; Bambury RM; O'Donnell PH; Gupta S; Guancial EA; Sonpavde GP; Faltaos D; Potvin D; Christensen JG; Chao RC; Rosenberg JE
Cancer; 2019 Feb; 125(4):533-540. PubMed ID: 30570744
[TBL] [Abstract][Full Text] [Related]
45. Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with
Qualls D; Noy A; Straus D; Matasar M; Moskowitz C; Seshan V; Dogan A; Salles G; Younes A; Zelenetz AD; Batlevi CL
Leuk Lymphoma; 2023 Mar; 64(3):738-741. PubMed ID: 36642966
[No Abstract] [Full Text] [Related]
46. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner.
Yumimoto K; Akiyoshi S; Ueo H; Sagara Y; Onoyama I; Ueo H; Ohno S; Mori M; Mimori K; Nakayama KI
J Clin Invest; 2015 Feb; 125(2):621-35. PubMed ID: 25555218
[TBL] [Abstract][Full Text] [Related]
47.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
48. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
Dobashi A
J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
[TBL] [Abstract][Full Text] [Related]
49. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
50. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells.
O'Hayre M; Inoue A; Kufareva I; Wang Z; Mikelis CM; Drummond RA; Avino S; Finkel K; Kalim KW; DiPasquale G; Guo F; Aoki J; Zheng Y; Lionakis MS; Molinolo AA; Gutkind JS
Oncogene; 2016 Jul; 35(29):3771-80. PubMed ID: 26616858
[TBL] [Abstract][Full Text] [Related]
51. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Krysiak K; Gomez F; White BS; Matlock M; Miller CA; Trani L; Fronick CC; Fulton RS; Kreisel F; Cashen AF; Carson KR; Berrien-Elliott MM; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
Blood; 2017 Jan; 129(4):473-483. PubMed ID: 28064239
[TBL] [Abstract][Full Text] [Related]
52. Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
Lee MJ; Koff JL; Switchenko JM; Jhaney CI; Harkins RA; Patel SP; Dave SS; Flowers CR
Cancer; 2020 Aug; 126(15):3493-3503. PubMed ID: 32469082
[TBL] [Abstract][Full Text] [Related]
53. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
[TBL] [Abstract][Full Text] [Related]
54. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
[TBL] [Abstract][Full Text] [Related]
55. The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.
Wu W; Jiang Y; Xing D; Zhai Y; Sun H; He X; Luo K; Xu P; Pan F; Dong G; Ren G; Zhao Z
Cell Death Discov; 2024 May; 10(1):206. PubMed ID: 38693103
[TBL] [Abstract][Full Text] [Related]
56. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
57. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
58. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.
Zimmer SN; Zhou Q; Zhou T; Cheng Z; Abboud-Werner SL; Horn D; Lecocke M; White R; Krivtsov AV; Armstrong SA; Kung AL; Livingston DM; Rebel VI
Blood; 2011 Jul; 118(1):69-79. PubMed ID: 21555743
[TBL] [Abstract][Full Text] [Related]
59. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Mondello P; Tadros S; Teater M; Fontan L; Chang AY; Jain N; Yang H; Singh S; Ying HY; Chu CS; Ma MCJ; Toska E; Alig S; Durant M; de Stanchina E; Ghosh S; Mottok A; Nastoupil L; Neelapu SS; Weigert O; Inghirami G; Baselga J; Younes A; Yee C; Dogan A; Scheinberg DA; Roeder RG; Melnick AM; Green MR
Cancer Discov; 2020 Mar; 10(3):440-459. PubMed ID: 31915197
[No Abstract] [Full Text] [Related]
60. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
Tillinghast GW; Partee J; Albert P; Kelley JM; Burtow KH; Kelly K
Genes Chromosomes Cancer; 2003 Jun; 37(2):121-31. PubMed ID: 12696060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
